# Ward Capoen

> Ward Capoen is a Series A investor at V-Bio Ventures backing Pharmaceutical and Biotechnology. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [V-Bio Ventures](https://shizune.co/investors/profile/v-bio-ventures)
- Location: Gent, Belgium
- Total investments: 8
- Last investment: Oct 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ward-capoen-71078240/

Ward Capoen is a Series A investor at V-Bio Ventures in Gent focused on Pharmaceutical and Biotechnology. Ward Capoen is based out of Ghent, Gent, Oost-Vlaanderen, and is the Partner of V-Bio Ventures and also Board Member of Step Pharma. Ward previously worked at Augustine Therapeutics as a Board Member. Ward Capoen attended the Vlerick Business School. .

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 4 | 50% |
| Biotechnology | 3 | 38% |
| Therapeutics | 2 | 25% |
| Medical | 1 | 13% |
| Biopharma | 1 | 13% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 50% |
| Seed | 2 | 25% |
| Series C | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 3 | 38% |
| Italy | 1 | 13% |
| Belgium | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Step Pharma | Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M | Series C | Oct 15, 2025 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M | Series A | Mar 24, 2025 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M | Series A | Jun 26, 2024 |  |
| Corteria Pharmaceuticals | Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $69.5M | Series A | Sep 07, 2023 |  |
| Sibylla Biotech | Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. | $23M | Series A | Oct 04, 2022 |  |
| Corteria Pharmaceuticals | Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $13.6M | Seed | Dec 09, 2021 |  |
| Biodol Therapeutics | Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics. | $5.4M | Series A | Aug 31, 2020 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $4.6M | Seed | Dec 16, 2019 |  |

8 of 8 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 5 deals together
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 3 deals together
- [Jeito Capital](https://shizune.co/investors/profile/jeito-capital) — VC Fund, 3 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 3 deals together
- [VIB](https://shizune.co/investors/profile/vib) — VC Fund, 3 deals together
- [AdBio partners](https://shizune.co/investors/profile/advent-france-biotechnology) — VC Fund, 2 deals together

## About V-Bio Ventures

VC Fund · Gent, Belgium

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

4 contacts available at V-Bio Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Shelley Margetson | Managing Partner | https://shizune.co/investors/profile/shelley-margetson |
| Willem Broekaert | Managing Partner | https://shizune.co/investors/profile/willem-broekaert |
| Christina Takke | Managing Partner | https://shizune.co/investors/profile/christina-takke |
| Ward Capoen | Partner | https://shizune.co/investors/profile/ward-capoen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ward Capoen invest in?

Ward Capoen invests primarily in Pharmaceutical, Biotechnology and Therapeutics startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ward Capoen last invest?

The most recent investment recorded for Ward Capoen closed in Oct 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co